Virtual Screening.

Slides:



Advertisements
Similar presentations
Analysis of High-Throughput Screening Data C371 Fall 2004.
Advertisements

1 Sequential Screening S. Stanley Young NISS HTS Workshop October 25, 2002.
PhysChem Forum, 29 Nov 2006, Newhouse 1 Memories and the future: From experimental to in silico physical chemistry Han van de Waterbeemd AstraZeneca, DMPK.
3D Molecular Structures C371 Fall Morgan Algorithm (Leach & Gillet, p. 8)
Ionization and dissociation of drugs-1
PharmaMiner: Geometric Mining of Pharmacophores 1.
Background Goals Methods Results Conclusions Implications.
Lipinski’s rule of five
Cheminformatics II Apr 2010 Postgrad course on Comp Chem Noel M. O’Boyle.
Two Examples of Docking Algorithms With thanks to Maria Teresa Gil Lucientes.
Summary Molecular surfaces QM properties presented on surface Compound screening Pattern matching on surfaces Martin Swain Critical features Dave Whitley.
Quantative Structure- Activity Relationships. Why QSAR? The number of compounds required for synthesis in order to place 10 different groups in 4 positions.
Quantitative Structure-Activity Relationships (QSAR) Comparative Molecular Field Analysis (CoMFA) Gijs Schaftenaar.
FLEX* - REVIEW.
Bioinformatics IV Quantitative Structure-Activity Relationships (QSAR) and Comparative Molecular Field Analysis (CoMFA) Martin Ott.
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Molecular Docking Using GOLD Tommi Suvitaival Seppo Virtanen S Basics for Biosystems of the Cell Fall 2006.
Chemoinformatics in Drug Design
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Structure-based Drug Design
Quantitative Structure-Activity Relationships (QSAR)  Attempts to identify and quantitate physicochemical properties of a drug in relation to its biological.
QSAR Qualitative Structure-Activity Relationships Can one predict activity (or properties in QSPR) simply on the basis of knowledge of the structure of.
Pharmacophore and FTrees
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Molecular Descriptors
Functional groups / Pharmacological Activity
Similarity Methods C371 Fall 2004.
A genetic algorithm for structure based de-novo design Scott C.-H. Pegg, Jose J. Haresco & Irwin D. Kuntz February 21, 2006.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
David Kim Allergan Inc. SoCalBSI California State University, Los Angeles.
Use of Machine Learning in Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds.
Altman et al. JACS 2008, Presented By Swati Jain.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA Junmei Wang,
Selecting Diverse Sets of Compounds C371 Fall 2004.
R L R L L L R R L L R R L L water DOCKING SIMULATIONS.
PharmaMiner: Geometric Mining of Pharmacophores 1.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Chapter 6. pKa & Chapter 7. Solubility
Chemistry XXI Unit 3 How do we predict properties? M1. Analyzing Molecular Structure Predicting properties based on molecular structure. M4. Exploring.
Use of Machine Learning in Chemoinformatics
Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine Ajay N. Jain UCSF Cancer Research Institute and Comprehensive.
Molecular mechanics Classical physics, treats atoms as spheres Calculations are rapid, even for large molecules Useful for studying conformations Cannot.
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Molecular Modeling in Drug Discovery: an Overview
Julia Salas CS379a Aim of the Study To determine distinguishing features of orally administered drugs –Physical and structural features probed.
A new protein-protein docking scoring function based on interface residue properties Reporter: Yu Lun Kuo (D )
Natural products from plants
Jump to first page Relational Data. Jump to first page Inductive Logic Programming (ILP) n Can use ILP to find a set of rules capturing a property that.
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
Homology Modeling and Docking to Potential Novel Inhibitor for
Simplified picture of the principles used for multiple copy simultaneous search (MCSS) and for computational combinatorial ligand design (CCLD). Simplified.
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
DATA MINING FOR SMALL MOLECULE ALLOSTERIC INHIBITORS
Molecular Docking Profacgen. The interactions between proteins and other molecules play important roles in various biological processes, including gene.
Building Hypotheses and Searching Databases
Rules for Rapid Property Profiling from Structure
Current Status at BioChemtek
Ligand Docking to MHC Class I Molecules
An Integrated Approach to Protein-Protein Docking
Cheminformatics Basics
ORGANIC PHARMACEUTICAL CHEMISTRY IV
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Mr.Halavath Ramesh 16-MCH-001 Dept. of Chemistry Loyola College University of Madras-Chennai.
Presentation transcript:

Virtual Screening

INTRODUCTION Virtual screening – Computational or in silico analog of biological screening Score, rank, and/or filter a set of structures using one or more computational procedures Helps decide: Which compounds to screen Which libraries to synthesize Which compounds to purchase from an external source Also used to analyze the results of HTS screening runs

Ways to Assess Structures from a Virtual Screening Experiment Use a previously derived mathematical model that predicts the biological activity of each structure Run substructure queries to eliminate molecules with undesirable functionality Use a docking program to ID structures predicted to bind strongly to the active site of a protein (if target structure is known) Filters remove structures not wanted in a succession of screening methods

Main Classes of Virtual Screening Methods Depend on the amount of structural and bioactivity data available One active molecule known: perform similarity search (ligand-based virtual screening) Several active molecules known: try to ID a common 3D pharmacophore, then do a 3D database search Reasonable number of active and inactive structures known: train a machine learning technique 3D structure of the protein known: use protein-ligand docking

Virtual Screening Methods for Non-Specific Targets Prediction of the likelihood that a molecule has “drug-like” characteristics and possesses desired physicochemical properties

“DRUG-LIKENESS” AND COMPOUND FILTERS Which features of drug molecules confer biological activity? Substructure filters to eliminate molecules known to have problems For a specific target, may have to modify or extend the filters Analyze the values of simple properties (MW, logP, No. of rotatable bonds)

Lipinski Rule of Five Poor absorption or permeation is more likely when: MW > 500 LogP >5 More than 5 H-bond donors (sum of OH and NH groups) More than 10 H-bond acceptors (sum of N and O atoms)

Other Findings 70% of drug-like molecules have: Between 0 and 2 H-bond donors Between 2 and 9 H-bond acceptors Between 2 and 8 rotatable bonds Between 1 and 4 rings Other techniques (neural networks, genetic algorithms, decision trees) consider more complex possibilities

“Lead-Likeness” Increase in molecular complexity occurs during optimization phase of a lead molecule

STRUCTURE-BASED VIRTUAL SCREENING Protein-Ligand Docking Aims to predict 3D structures when a molecule “docks” to a protein Need a way to explore the space of possible protein-ligand geometries (poses) Need to score or rank the poses to ID most likely binding mode and assign a priority to the molecules Problem: involves many degrees of freedom (rotation, conformation) and solvent effects Conformations of ligands in complexes often have very similar geometries to minimum-energy conformations of the isolated ligand

Protein-Ligand Docking Methods Modern methods explore orientational and conformational degrees of freedom at the same time Monte Carlo algorithms (change conformation of the ligand or subject the molecule to a translation or rotation within the binding site Genetic algorithms Incremental construction approaches Problem: Lack of a comprehensive knowledge base

Distinguish “Docking” and “Scoring” Docking involves the prediction of the binding mode of individual molecules Goal: ID orientation closest in geometry to the observed X-ray structure Scoring ranks the ligands using some function related to the free energy of association of the two units DOCK function looks at atom pairs of between 2.3-3.5 Angstroms Pair-wise linear potential looks at attractive and repulsive regions, taking into account steric and hydrogen bonding interactions

Structure-Based Virtual Screening: Other Aspects Computationally intensive and complex Multitude of possible parameters figure into docking programs Docking programs require 3D conformation as the starting point or require partial atomic charges for protein and ligand X-Ray Crystallographic studies don’t include hydrogens, but most docking programs require them

PREDICTION OF ADMET PROPERTIES Requirements for a drug: Must bind tightly to the biological target in vivo Must pass through one or more physiological bariers (cell membrane or blood-brain barrier) Must remain long enough to take effect Must be removed from the body by metabolism, excretion, or other means ADMET: Absorption, Distribution, metabolism, Excretion (Elimination), Toxicity

ADMET (cont’d) Permeability through the intestinal cell membrane or blood-brain barrier Paucity of experimental data in vivo studies, especially for humans

Hydrogen Bonding Descriptors Count of the numbers of donors and acceptors Calculation of the overall propensity to be an acceptor or donor Modeling solubility, octanol/water partition coefficient, and blood-brain barrier permeability

Polar Surface Area Amount of molecular surface due to polar atoms (N and O plus attached hydrogens) Especially good for prediction of oral absorption and brain penetration Polar surface are greater than 140 square Angstroms has been associated with poor absorption

Descriptors Based on 3D Fields Molecular descriptors quantify the molecule’s overall size and shape and the balance between hydrophilicity, hydrophobicity, and hydrogen bonding

Toxicity Prediction Very difficult problem Most limit studies to single toxicological phenomenon or a single class of compounds (e.g., Polycyclic aromatic hydrocarbons) Some based on known toxic effects

SUMMARY Virtual screening methods are central to many cheminformatics problems in: Design Selection Analysis Increasing numbers of molecules can be evaluated using these techniques Reliability and accuracy remain as problems in docking and predicting ADMET properties Need much more reliable and consistent experimental data